Clinicopathologic features and adverse effects of different oral As2O3 maintenance regimens in 76 patients
| . | Regimen A (N = 20) . | Regimen AA (N = 19) . | Regimen AAA (N = 37) . | P . |
|---|---|---|---|---|
| Clinicopathologic features | ||||
| Male | 12 | 8 | 15 | NS (.34) |
| Age > 40 y | 13 | 13 | 24 | NS (.96) |
| Presentation WBC count > 10 × 109/L | 2 | 5 | 3 | NS (.14) |
| Presentation platelet count < 40 × 109/L | 14 | 14 | 23 | NS (.65) |
| APL differentiation syndrome | 5 | 6 | 5 | NS (.26) |
| Peak WBC count > 10 × 109/L | 8 | 11 | 16 | NS (.48) |
| Second solid tumor (before/after) maintenance | 3 | 3 | 8 | NS (.78) |
| Adverse effects | ||||
| Headache | 3 | 11 | 8 | .005 |
| Liver function derangement | 6 | 3 | 8 | NS (.56) |
| Herpes zoster reactivation | 2 | 5 | 3 | NS (.14) |
| Rash | 2 | 3 | 3 | NS (.67) |
| Dyspepsia | 3 | 4 | 11 | NS (.43) |
| . | Regimen A (N = 20) . | Regimen AA (N = 19) . | Regimen AAA (N = 37) . | P . |
|---|---|---|---|---|
| Clinicopathologic features | ||||
| Male | 12 | 8 | 15 | NS (.34) |
| Age > 40 y | 13 | 13 | 24 | NS (.96) |
| Presentation WBC count > 10 × 109/L | 2 | 5 | 3 | NS (.14) |
| Presentation platelet count < 40 × 109/L | 14 | 14 | 23 | NS (.65) |
| APL differentiation syndrome | 5 | 6 | 5 | NS (.26) |
| Peak WBC count > 10 × 109/L | 8 | 11 | 16 | NS (.48) |
| Second solid tumor (before/after) maintenance | 3 | 3 | 8 | NS (.78) |
| Adverse effects | ||||
| Headache | 3 | 11 | 8 | .005 |
| Liver function derangement | 6 | 3 | 8 | NS (.56) |
| Herpes zoster reactivation | 2 | 5 | 3 | NS (.14) |
| Rash | 2 | 3 | 3 | NS (.67) |
| Dyspepsia | 3 | 4 | 11 | NS (.43) |
Regimen A indicates As2O3; Regimen AA, ATRA + As2O3; and Regimen AAA, ATRA + As2O3 + ascorbic acid.